公开(公告)号：US11773106B2

公开(公告)日：2023-10-03

申请号：US18176850

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Aileen L. Pangan ,  In-Ho Song ,  Ben Klünder ,  Jeffrey W. Voss ,  Robert J. Padley ,  Heidi S. Camp

IPC: A61K31/4985 ,  C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

公开(公告)号：US20160326181A1

公开(公告)日：2016-11-10

申请号：US15152823

申请日：2016-05-12

Applicant: AbbVie Inc.

Inventor： Neil Wishart ,  Maria A. Argiriadi ,  David J. Calderwood ,  Anna M. Ericsson ,  Bryan R. Fiamengo ,  Kristine E. Frank ,  Michael M. Friedman ,  Dawn M. George ,  Eric R. Goedken ,  Nathan S. Josephsohn ,  Biqin C. Li ,  Michael J. Morytko ,  Kent D. Stewart ,  Jeffrey W. Voss ,  Grier A. Wallace ,  Lu Wang ,  Kevin R. Woller

IPC: C07D487/14

CPC classification number: C07D487/14 ,  C07D498/14 ,  C07D513/14

Abstract: The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract translation: 药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：US20140205613A1

公开(公告)日：2014-07-24

申请号：US14160253

申请日：2014-01-21

Applicant: AbbVie Inc.

Inventor： Jeffrey W. Voss ,  Carolyn A. Cuff

IPC: G01N33/68 ,  C12Q1/68 ,  A61K39/395

CPC classification number: G01N33/6863 ,  A61K39/3955 ,  C12Q1/6883 ,  G01N2333/522 ,  G01N2333/525 ,  G01N2333/54 ,  G01N2800/52

Abstract: The invention provides methods for predicting the efficacy of anti-TNF and anti-IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.

Abstract translation: 本发明提供了通过确定来源于受试者的样品中的CXCL1和/或CXCL5标志物水平来预测抗TNF和抗IL17联合疗法在治疗患有炎性疾病的受试者中的功效的方法。